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Abstract
Background Bowel cancer screening increases early stage disease detection and reduces cancer-specific mortality.
We assessed the relationship between co-morbidity, screen-detection and survival in colorectal cancer.
Methods A retrospective, observational cohort study compared screen-detected (SD) and non-screen-detected (NSD)
patients undergoing potentially curative resection (April 2009–March 2011). Co-morbidity was quantified using
ASA, Lee and Charlson Indices. Systemic inflammatory response was measured using the neutrophil lymphocyte
ratio (NLR). Covariables were compared using crosstabulation and the v2 test for linear trend. Survival was analysed
using Cox Regression.
Results Of 770 patients, 331 had SD- and 439 NSD-disease. A lower proportion of SD patients had a high ASA (C3)
compared to NSD (27.2% vs 37.3%; p = 0.007). There was no significant difference in the proportion of patients with
a high (C2) Lee Index (16.3% SD vs 21.9% NSD; p = 0.054) or high (C3) Charlson Index (22.7% SD vs 26.9%
NSD; p = 0.181). On univariate analysis, NSD (HR 2.182 (1.594–2.989;p\ 0.001)), emergency presentation (HR
3.390 (2.401–4.788; p\ 0.001)), advanced UICC-TNM (III or IV) (p\ 0.001), high ASA (C3) (HR 1.857
(1.362–2.532; p\ 0.001)), high Charlson Index (C3) (HR 1.800 (1.333–2.432; p\ 0.001)) and high (C3) NLR (HR
1.825 (1.363–2.442; p\ 0.001)) were associated with poorer overall survival (OS). NSD predicted poorer cancer-
specific survival (CSS) (HR 2.763 (1.776–4.298; p\ 0.001)). On multivariate analysis, NSD retained significance as
an independent predictor of poorer OS (HR 1.796 (1.224–2.635; p = 0.003)) and CSS (HR 1.924 (1.193–3.102;
p = 0.007)).
Conclusions Patients with SD cancers have significantly lower ASA scores. After adjusting for ASA, co-morbidity
and a broad range of covariables, SD patients retain significantly better OS and CSS.
Introduction
Colorectal cancer is the fourth most common cancer in the
UK, with approximately 41,000 new cases and 16,000
deaths each year [1]. The Scottish Bowel Screening
Programme was introduced in 2007 and involved a com-
bined guaiac-based faecal occult blood (gFOBt) and faecal
immunochemical test (FIT) followed by colonoscopy for
those patients testing positive [2]. More recently that has
changed to a quantitative FIT-based programme. Patients
aged between 50 and 74 years are invited for screening in
Scotland. There is good evidence to suggest that this
approach to screening increases the number of early stage
cancers diagnosed and reduces cancer-specific mortality
[3–6]. Additionally, some evidence suggests the incidence
of colorectal cancer may be reduced through the removal of
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precursor polyps and that the requirement for more inva-
sive surgical procedures may be reduced due to earlier
diagnosis [6].
A number of studies have attempted to characterise the
inherent differences between screen-detected (SD) and
non-screen-detected (NSD) cancer in terms of patient and
tumour factors. Patients who have cancers detected at
screening are more likely to be male, younger, less
socioeconomically deprived have a lower systemic
inflammatory response (SIR) and in those undergoing
resection, to have lower T staging, less venous invasion,
less peritoneal involvement and less margin involvement
[7–9]. Co-morbidity is an important host factor that to date
has not been studied in detail within the context of col-
orectal cancer screening outcomes. It has previously been
shown that patients with screen-detected disease have a
lower burden of co-morbidity due to their demographic
profile, and that this may influence post-operative outcome
[10]. However, the effect on long-term outcome and the
potential for confounding by the SIR remains unclear. The
aim of the present study was to assess the relationship
between co-morbidity, screen-detection and overall sur-
vival in patients with colorectal cancer.
Material and methods
A retrospective observational cohort study was conducted.
The cohort was obtained from all patients invited to par-
ticipate in the first complete round of the Scottish Bowel
Screening Programme in NHS Greater Glasgow and Clyde
(NHS GG&C) between April 2009 and the end of March
2011. As per the Scottish bowel cancer screening pro-
gramme protocol, this involves those aged 50–74 years. To
identify patients with non-screen-detected colorectal can-
cers diagnosed during the same time period and within the
same health board, the West of Scotland Colorectal Cancer
Managed Clinical Network (MCN) dataset and the Scottish
Cancer Registry (SMR06) datasets were cross-referenced.
In Scotland, colonoscopy is only routinely performed in
asymptomatic individuals within the screening programme
and so all non-screen-detected patients were scoped via
symptomatic referral pathways. Further details on the
identification of this cohort have previously been described
[8].
Baseline demographics, co-morbidity, body mass index
(BMI), American Society of Anaesthesiology grade (ASA)
and survival were obtained on a case-by-case basis from
NHS electronic patient records and theatre records. Patients
were excluded from the final analysis if they did not
undergo a surgical resection with curative intent or if their
records were absent from the NHS electronic portal system.
Co-morbidity was objectively quantified using ASA and
two validated co-morbidity scoring systems: the Lee Index
and the Charlson Index. The American Society of Anaes-
thesiology grade is the gold standard system for assessing a
patient’s preoperative physical status and medical co-
morbidities and ranges from I for a normal healthy patient
to V for a moribund patient not expected to survive with or
without surgery. For the purposes of the analysis, an ASA
grade of I-II was classified as low and an ASA of III-V as
high. The Lee Index is a co-morbidity score which was
developed to predict the risk of cardiac complications
among patients undergoing non-cardiac surgery. It is based
on six variables: a history of coronary artery disease,
congestive heart failure, cerebrovascular disease, diabetes
mellitus requiring insulin therapy, chronic kidney disease
(defined as a preoperative serum creatinine[2 mg/dl) and
whether the patient is due to undergo high-risk surgery
(defined as intraperitoneal, intrathoracic or suprainguinal
vascular surgery) [11]. As patients were only included in
this study if they had undergone a colorectal resection, all
patients scored at least 1 and a high Lee Index was defined
as a score C2. The Charlson Index was developed to
objectively quantify co-morbidity and associated mortality
risk for the specific purpose of use in longitudinal studies.
It is based on a history of myocardial infarction, congestive
cardiac failure, peripheral vascular disease, cerebrovascu-
lar disease, dementia, chronic lung disease, connective
tissue disease, peptic ulcer, diabetes mellitus (with or
without end-organ damage), chronic kidney disease,
hemiplegia, leukaemia, lymphoma, solid tumours (either
localised or metastatic), liver disease (mild or moderate to
severe) and AIDS [12]. A high Charlson Index was defined
as a score C3.
Systemic inflammatory response (SIR) was quantified
using the previously validated neutrophil/lymphocyte ratio
(NLR). A greater SIR is associated with a high NLR (C3).
Statistics
Covariables were compared using crosstabulation and the
v2 test for a linear trend. A value of P\ 0.05 was con-
sidered statistically significant. Overall, survival (OS) and
cancer-specific survival (CSS) were analysed using Cox
Regression. All covariables found to be statistically sig-
nificant (P\ 0.05) predictors of survival on univariate
analysis were carried forward to a multivariate survival
analysis. A stepwise backward method was used to produce
a final model of variables with a significant independent
impact on survival, where variables were removed from the
model when the corresponding P value was[0.05. Sta-
tistical analysis was performed using SPSS software (SPSS





Of all 395,097 patients invited to participate in the first
complete round of screening in NHS GG&C, 204,535
(52%) responded of which 6,159 (3%) tested positive. Of
those testing positive, 4797 (78%) proceeded to colono-
scopy and 421 (9%) of those patients were found to have a
colorectal malignancy. There were 708 patients with non-
screen-detected colorectal cancers diagnosed in NHS
GG&C during the same time period of which 468 (65%) of
these were non-responders to the screening programme,
182 (25%) were interval cancers (within two years of a
negative screening test), 43 (6%) were individuals who
chose not to attend colonoscopy and 15 (2%) had no
malignancy detected at index colonoscopy. Of the 1129
total (421 screen-detected and 708 non-screen-detected),
770 patients underwent a surgical resection with curative
intent and had complete NHS electronic portal records and
were included in the final analysis. A total of 331 (43%) of
these patients had screen-detected (SD) and 439 (57%) had
non-screen-detected (NSD) disease (Fig. 1).
Demographics
Of all 770 patients included in the study, the median age
was 67 years, 456 (59%) were males and 247 (37%) had
rectal cancer. UICC-TNM distribution was stage I 234
(30%), II 262 (34%), III 236 (31%), IV 38 (5%). The SIR
was elevated in 326 (43%) of all patients as measured by a
high NLR (C3).
A comparison of demographics between SD and NSD
patients can be seen in Table 1. As has been reported
previously in this cohort, patients with SD disease were
significantly more likely to be male (64.4% vs 55.4%;
p = 0.012), have an earlier UICC-TNM stage (p = 0.001),
have colonic tumours (73.7% vs 63.4%; p = 0.002) and
had a lower rate of emergency presentations (0.6% vs
17.1%; p\ 0.001). Two (0.6%) screen-detected patients
required emergency operations. The first was admitted for
elective laparoscopic right hemicolectomy following pos-
itive screening, but on admission had clinical and radio-
logical evidence of obstruction and perforation
necessitating laparotomy and the second attended for
colonoscopy following a positive screening test and was
clinically and radiologically obstructed and was taken for
an emergency subtotal colectomy. SD patients were less
likely to have evidence of a SIR as measured by an ele-
vated (C3) NLR (33.7% vs 49.7%; p\ 0.001).
Co-Morbidity
Examining co-morbidity indices, SD patients were less
likely to have a high (C3) ASA score as compared to NSD
patients (27.2% vs 37.3%; p = 0.007). There was no dif-
ference in the proportion of patients with a high (C2) Lee
Index (16.3% SD vs 21.9% NSD; p = 0.054) or high (C3)
Charlson Index score (23% SD vs 27% NSD; p = 0.181)
between the groups.
Survival
With a median follow-up of 63 months (range
33–83 months), 188 (24%) patients died of which 106
(56%) patients died of colorectal cancer. Eight (1%) died
within 30 days of their operation (4 SD, 4 NSD). 5 year
overall survival (OS) and cancer-specific survival (CSS)
were 77% (168 deaths, 361 patients reaching 5 year fol-
low-up) and 85% (100 deaths, 361 patients reaching 5 year
follow-up), respectively.
Table 2 and Table 3 display the outcomes of both uni-
variate and multivariate survival analysis for OS and CSS,
respectively. On univariate analysis, non-screen-detection
Fig. 1 Flow chart of patient identification
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(HR 2.182 (1.594–2.989; p\ 0.001)) (Fig. 2), emergency
presentation (HR 3.390 (2.401–4.788; p\ 0.001)),
advanced UICC-TNM stage (III or IV) (p\ 0.001)
(Fig. 3), high (C3) ASA (HR 1.857 (1.362–2.532;
p\ 0.001)) (Fig. 4), high (C3) Charlson Index (HR 1.800
(1.333–2.432; p\ 0.001)) (Fig. 5) and high (C3) NLR
(HR 1.825 (1.363–2.442; p\ 0.001)) (Fig. 6) were all
associated with poorer overall survival. Excluding post-
operative deaths, non-screen-detection (HR 2.763
(1.776–4.298; p\ 0.001)), emergency presentation (HR
5.141 (3.388–7.801; p\ 0.001)), advanced UICC-TNM
stage (III or IV) (p\ 0.001) and high (C3) NLR (HR 1.793
(1.219–2.639; p = 0.003)) were also associated with poorer
cancer-specific survival.









B62 254 (33.0%) 101 (30.5%) 153 (34.9%)
63–70 256 (33.2%) 120 (36.3%) 136 (31.0%)
C71 260 (33.8%) 110 (33.2%) 150 (34.2%)
Sex 0.012
Male 456 (59.2%) 213 (64.4%) 243 (55.4%)
Female 314 (40.8%) 118 (35.6%) 196 (44.6%)
Scottish Index of Multiple Deprivation 0.255
1 (most deprived) 254 (33.1%) 100 (30.3%) 154 (35.2%)
2 141 (18.4%) 54 (16.4%) 87 (19.9%)
3 129 (16.8%) 61 (18.5%) 68 (15.5%)
4 107 (13.9%) 51 (15.5%) 56 (12.8%)
5(least deprived) 137 (17.8%) 64 (19.4%) 73 (16.7%)
Presentation <0.001
Elective 693 (90.0%) 329 (99.4%) 364 (82.9%)
Emergency 77 (10.0%) 2 (0.6%) 75 (17.1%)
Tumour Site 0.002
Colon 521 (67.8%) 244 (73.7%) 277 (63.4%)
Rectum 247 (36.6%) 87 (26.3%) 160 (36.6%)
UICC-TNM Stage 0.001
I 234 (30.4%) 129 (39.0%) 105 (23.9%)
II 262 (34.0%) 91 (27.5%) 171 (39.0%)
III 236 (30.6%) 101 (30.5%) 135 (30.8%)
IV 38 (4.9%) 10 (3.0%) 28 (6.4%)
ASAa 0.007
Low (1–2) 439 (66.8%) 195 (72.8%) 244 (62.7%)
High (C3) 218 (33.2%) 73 (27.2%) 145 (37.3%)
Lee Index 0.054
Low 620 (80.5%) 277 (83.7%) 343 (78.1%)
High 150 (19.5%) 54 (16.3%) 96 (21.9%)
Charlson Index 0.181
Low 577 (74.9%) 256 (77.3%) 321 (73.1%)
High 193 (25.1%) 75 (22.7%) 118 (26.9%)
NLR <0.001
Low(\3) 435 (57.2%) 216 (66.3%) 219 (50.3%)
High (C3) 326 (42.8%) 110 (33.7%) 216 (49.7%)
Significant p values highlighted in bold
ASA American Society of Anaesthesiology grade; NLR neutrophil/ lymphocyte ratio
aData missing for 113 (14.7%) patients
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On multivariable analysis non-screen-detection (HR
1.661 (1.147–2.404; p = 0.007)), emergency presentation
(HR 2.190 (1.451–3.304; p\ 0.001)), advanced UICC-
TNM stage (III or IV) (p\ 0.001) and a high (C3)
Charlson Index (HR 1.732 (1.240–2.421; p = 0.001))
retained significance as independent predictors of overall
survival. Non-screen-detection (HR 1.924 (1.193–3.102;
p = 0.007)), emergency presentation (HR 2.557
(1.608–4.067; p\ 0.001)) and advanced UICC-TNM stage
(III or IV) (p\ 0.001) retained significance as independent
predictors of cancer-specific survival.
Table 2 Factors associated with overall survival in patients with colorectal cancer undergoing resection with a curative intent
Univariate Multivariable
H.R 95% C.I p value H.R 95% C.I p value
Age
\62 1.0
63–70 1.075 0.743–1.555 0.702
C71 1.353 0.952–1.924 0.092
Sex
Male 1.0
Female 0.968 0.721–1.299 0.828
Screen Detected
Yes 1.0 1.0
No 2.182 1.594–2.989 <0.001 1.661 1.147–2.404 0.007
SIMD
Non-deprived 1.0
Deprived 1.242 0.931–1.658 0.141
Presentation
Elective 1.0 1.0
Emergency 3.390 2.401–4.788 <0.001 2.190 1.451–3.304 <0.001
Tumour Site
Colon 1.0
Rectum 1.035 0.757–1.414 0.832
UICC-TNM Stage
I 1.0 1.0
II 1.570 1.011–2.439 0.045 1.161 0.709–1.902 0.552
III 2.650 1.751–4.010 <0.001 2.374 1.501–3.755 <0.001
IV 8.567 5.147–14.261 <0.001 6.727 3.814–11.862 <0.001
ASA
Low 1.0 1.0
High 1.857 1.362–2.532 <0.001 1.260 0.893–1.778 0.189
Lee Index
Low 1.0 1.0
High 1.403 1.004–1.959 0.047 0.912 0.607–1.370 0.657
Charlson Index
Low 1.0 1.0
High 1.800 1.333–2.432 <0.001 1.732 1.240–2.421 0.001
NLR
Low 1.0 1.0
High 1.825 1.363–2.442 <0.001 1.271 0.933–1.794 0.122
Significant p values highlighted in bold




The present study provides a comprehensive analysis of
outcome in patients diagnosed with colorectal cancer fol-
lowing an invite to participate in the first round of the
Scottish Bowel Screening Programme in our geographical
area. It has identified that patients with screen-detected
disease have tumours of an earlier UICC-TNM stage, have
a lower systemic inflammatory response and have lower
ASA scores than their non-screen-detected counterparts,
one measure of co-morbidity. In addition, it has re-con-
firmed that having a screen-detected tumour is an inde-
pendent prognostic factor for both improved overall and
cancer-specific survival.
Many studies have attempted to characterise both factors
that influence the uptake of bowel cancer screening and the
Table 3 Factors associated with cancer-specific survival in patients with colorectal cancer undergoing resection with a curative intent
Univariate Multivariable
H.R 95% C.I p value H.R 95% C.I p value
Age
\62 1.0
63–70 0.741 0.461–1.189 0.214
C71 0.875 0.556–1.377 0.563
Sex
Male 1.0
Female 1.036 0.702–1.528 0.859
Screen Detected
Yes 1.0 1.0
No 2.763 1.776–4.298 < 0.001 1.924 1.193–3.102 0.007
SIMD
Non-deprived 1.0
Deprived 1.020 0.695–1.495 0.920
Presentation
Elective 1.0 1.0
Emergency 5.141 3.388–7.801 < 0.001 2.557 1.608–4.067 < 0.001
Tumour Site
Colon 1.0
Rectum 1.208 0.787–1.853 0.388
UICC-TNM Stage
I 1.0 1.0
II 2.153 0.980–4.730 0.056 1.585 0.714–3.521 0.258
III 6.405 3.149–13.027 <0.001 5.116 2.490–10.509 < 0.001
IV 30.064 14.054–64.313 <0.001 19.814 9.039–43.430 < 0.001
ASA
Low 1.0
High 1.321 0.868–2.009 0.194
Lee Index
Low 1.0
High 1.245 0.784–1.977 0.354
Charlson Index
Low 1.0
High 1.293 0.843–1.983 0.240
NLR
Low 1.0 1.0
High 1.793 1.219–2.639 0.003 1.209 0.807–1.810 0.358
Significant p values highlighted in bold
ASA American Society of Anaesthesiology grade; NLR neutrophil/ lymphocyte ratio
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inherent differences between screen-detected (SD) and
non-screen-detected (NSD) cancer in terms of patient and
tumour factors. For example, lower uptake of bowel
screening has been shown to be associated with younger
age, male sex and socioeconomic deprivation [7]. In
agreement with previous work [7–9, 13], screen-detected
patients in this study were more likely to be male, less
likely to have rectal cancers and there was a non-significant
trend towards lower socioeconomic deprivation. As would
be expected, SD tumours were of a significantly lower
UICC-TNM stage and there were a significantly lower
number of emergency operations in this group. The NLR is
a previously validated method of quantifying the systemic
Number at Risk
NSD 439 414  380 329 220 93 21
SD 331 321 309 302 259 162 50
Number at Risk
NSD 430 407  376 327 217 92 20
SD 324 319 307 301 257 159 48
Fig. 2 Relationship between screen detection and OS and CSS
Number at Risk
Stage I 234 228 224 212 168 90 26
Stage II 262 250 238 219 164 89 23
Stage III 236 225 202 180 136 69 21
Stage IV 38 32 25 20 12 7 2
Number at Risk
Stage I 230 227 222 211 166 88 24
Stage II 255 248 237 217 163 87 22
Stage III 232 220 200 180 134 69 20
Stage IV 38 32 25 20 11 7 2
Fig. 3 Relationship between UICC-TNM stage and OS and CSS
World J Surg
123
inflammatory response, with a higher NLR indicative of a
greater SIR. NLR was significantly higher among NSD
patients in this study.
The present study has added to existing work examining
the degree of comorbidity in patients with SD compared to
NSD colorectal cancer. Three measures of co-morbidity
were used including the ASA, Lee Index and Charlson
Index. Patients with SD disease were significantly less co-
morbid as measured by the ASA. While a higher proportion
of NSD patients had a high Lee Index co-morbidity score,
this did not reach statistical significance (16.3% SD vs
21.9% NSD; p = 0.054). The reason behind this disparity
in ASA scores is likely multifactorial and may reflect either
the underlying difference in co-morbidity between those
that choose to participate in the screening programme, or
the morbidity associated with presenting with more
advanced disease.
Indeed, the impact of co-morbidity on bowel cancer
screening uptake has been previously studied [14]. This
cross-sectional study which focussed on the Barcelona
population-based colorectal cancer screening programme
included 36,208 patients from 10 primary care centres with
17,404 (48%) of those participating in screening. Non-
participants were significantly more likely to be male,
socioeconomically deprived, smokers, have high-risk
alcohol intake, be obese or be in the highest co-morbidity
group. Having three or more dominant chronic diseases
was associated with lower participation in the screening
programme (incidence rate ratio IRR 0.76, 95% CI
0.65–0.89; p = 0.001) [14]. In addition, there is evidence
that co-morbidity may be associated with non-participation
in breast and cervical cancer screening programmes [15]. It
is therefore conceivable that significant co-morbidity could
act as a barrier to participating in the Scottish Bowel
Screening Programme.
One previous study has examined the impact of screen-
detection and co-morbidity on post-operative morbidity in
patients undergoing resection for colorectal cancer. In this
previous retrospective study from Spain of just under 200
patients, there was no significant difference between the
SD and NSD groups in terms of ASA or Charlson Index,
however, the percentage of patients with low ASA scores (I
or II) was greater in the SD group [13].
The present study has a number of strengths related to its
large numbers and level of detail regarding co-morbid
disease. In addition, it is the first to report on the impact of
the SIR on outcome in patients with screen-detected col-
orectal cancer. However, despite this, as a retrospective
cohort study, ASA data were missing for 15% of patients.
In addition, the effect of lead-time bias, where earlier
detection artificially lengthens a patient’s survival follow-
ing a cancer diagnosis, has not been taken into account.
However, adjusting for this confounder within the context
of a retrospective cohort study is complex and out with the
scope of the present study.
Number at Risk
Low 439 425 405 369 266 129 35
High 218 202 184 169 124 60 14
Number at Risk
Low 433 423 403 368 264 128 33
High 211 197 182 166 121 58 13




Patients with screen-detected disease have tumours of an
earlier stage, have lower ASA scores and are less likely to
have evidence of a SIR than their non-screen-detected
counterparts. However, after adjusting for these co-vari-
ables, screen-detection retains significance as an indepen-
dent predictor of improved overall and cancer-specific
survival.
Therefore, yet undetermined inherent differences
between SD and NSD patients remain and should be a
focus of ongoing research.
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Number at Risk
Low 577 563 533 488 369 200 55
High 193 172 156 143 110 55 16
Number at Risk
Low 571 558 529 486 367 197 53
High 183 169 154 142 107 54 15
Fig. 5 Relationship between Charlson Index and OS and CSS
Number at Risk
Low 435 420 405 372 284 155 55
High 326 306 276 251 188 97 25
Number at Risk
Low 429 418 401 371 282 152 43
High 317 300 275 249 186 96 24
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